Skip to main navigation
Skip to search
Skip to main content
Sort by
Neuroscience
Meta-Analysis
100%
Clozapine
60%
In Vivo
44%
Antipsychotic
42%
Major Depressive Disorder
40%
Bipolar Disorder
40%
Translocator Protein
40%
Negative Syndrome
31%
Positive Syndrome
31%
positron emission tomographic scan
28%
Placebo
27%
Treatment-Resistant Schizophrenia
24%
Depressive Disorder
24%
Therapeutic Antibodies
20%
Bipolar I Disorder
20%
Glucagon-Like Peptide-1 Agonist
20%
Paraphrenia
20%
ICD-10
20%
Systematic Review
20%
B Cell
20%
Receptor
17%
Natalizumab
15%
Dopamine Transporter
13%
Randomized Controlled Trial
12%
Olanzapine
12%
Body Mass Index
12%
High Density Lipoprotein Cholesterol
12%
Gray Matter
8%
Intravenous Immunoglobulin
8%
Dopamine Release
8%
Lurasidone
8%
Haloperidol
8%
Low Density Lipoprotein Cholesterol
8%
Triacylglycerol
8%
Metabolic Disorder
8%
Medicine and Dentistry
Systematic Review
80%
Meta-Analysis
40%
Clozapine
40%
Placebo
21%
Image Reconstruction
20%
Positron Emission Tomography
20%
COVID-19
20%
Regulatory Mechanism
20%
Major Depressive Episode
20%
Mental Health
20%
Glucagon-Like Peptide-1 Agonist
20%
Quality of Life
20%
Network Meta-Analysis
20%
Antipsychotic
20%
B Lymphocyte
20%
Brexpiprazole
12%
Cariprazine
12%
Body Mass Index
12%
High Density Lipoprotein Cholesterol
12%
Olanzapine
12%
Randomized Controlled Trial
10%
Adverse Event
8%
Diseases
8%
Immunoglobulin
8%
Telemedicine
8%
Receptor
8%
Fluorine-18
8%
Triacylglycerol
8%
Lurasidone
8%
Low Density Lipoprotein Cholesterol
8%
Water-Electrolyte Imbalance
8%
Haloperidol
8%
Side Effect
8%
Consultation
6%
Dopamine Release
6%
Dopamine Transporter
6%
Diabetes
6%
Treatment-Resistant Schizophrenia
6%
Clinical Study
6%
Pharmacology, Toxicology and Pharmaceutical Science
Clozapine
93%
Antipsychotic
41%
Side Effect
29%
Placebo
21%
Cross-Sectional Study
20%
SARS Coronavirus
20%
Prospective Study
20%
Glucagon Like Peptide 1 Receptor Agonist
20%
Cariprazine
12%
Olanzapine
12%
Brexpiprazole
12%
High Density Lipoprotein Cholesterol
12%
Randomized Controlled Trial
10%
Adverse Event
8%
Diseases
8%
Immunoglobulin
8%
Lurasidone
8%
4 (para chlorophenyl) 1 [3 (para fluorobenzoyl)propyl] 4 piperidinol
8%
Triacylglycerol
8%
Metabolic Disorder
8%
Low Density Lipoprotein Cholesterol
8%
Normal Human
6%
COVID-19 Vaccine
6%
Clinical Study
6%
Treatment-Resistant Schizophrenia
6%
